Inactive Instrument

Cardiovascular Systems, Inc.

Equities

CSII

US1416191062

Medical Equipment, Supplies & Distribution

Cardiovascular Systems : Bragar Eagel & Squire, P.C. : Is Investigating the Board of Directors of Cardiovascular Systems, Inc. (CSII) on Behalf of Stockholders and Encourages Investors to Contact the Firm

January 26, 2016 at 10:31 pm

Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Cardiovascular Systems, Inc. (NASDAQ:CSII) investors concerning whether the company’s board of directors violated their fiduciary duties.

On May 8, 2014, the company received a letter from the U.S. Attorney’s Office for the Western District of North Carolina stating that Cardiovascular Systems is being investigated for possible violations of the False Claims Act. On July 8, 2015, Cardiovascular Systems further revealed that a whistleblower lawsuit filed in 2013 had been unsealed alleging that Cardiovascular Systems engaged in a fraudulent marketing scheme to maximize profits through illegal kickbacks.

If you purchased Cardiovascular Systems securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact J. Brandon Walker, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information, please go to www.bespc.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160126006653/en/

Latest news about Cardiovascular Systems, Inc.

Orbusneich Medical Group Holdings Limited and Cardiovascular Systems, Inc. Enters into an Amendment to Distribution Agreement	27/09/23	CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P Healthcare Equipment Select Industry Index	01/05/23	CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P Composite 1500	01/05/23	CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P 600	01/05/23	CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P Global BMI Index	01/05/23	CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P 1000	01/05/23	CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P TMI Index	01/05/23	CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from S&P 600 Health Care	01/05/23	CI
Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from NASDAQ Composite Index	27/04/23	CI
Abbott Laboratories completed the acquisition of Cardiovascular Systems, Inc. from The Vanguard Group, Inc. and others.	26/04/23	CI
Wall St dips as Treasury yields rise after auction	09/02/23	RE
Wall St dips as Treasury yields rise after auction	09/02/23	RE
Wall St dips as Treasury yields rise; Disney hits 5-month high	09/02/23	RE
Top Midday Gainers	09/02/23	MT
Wall St dips as Alphabet extends fall; Disney hits 5-month high	09/02/23	RE
Sector Update: Health Care Stocks Mixed Premarket Thursday	09/02/23	MT
Top Premarket Gainers	09/02/23	MT
Abbott Laboratories Enters Deal to Acquire Cardiovascular Systems for $890 Million	09/02/23	MT
North American Morning Briefing : Stocks Seen -2-	09/02/23	DJ
North American Morning Briefing : Stocks Seen Bouncing Back, Next Catalysts Eyed	09/02/23	DJ
Cardiovascular Systems Shares Soar Premarket on Abbott Buyout	09/02/23	DJ
Cardiovascular Systems Fiscal Q2 Loss, Revenue Increases; Shares Rise Pre-Bell	09/02/23	MT
EMEA Morning Briefing : Investors to Parse Fed -2-	09/02/23	DJ
Abbott Laboratories to Acquire Cardiovascular Systems At Equity Value of $890 Million	08/02/23	DJ
Cardiovascular Systems, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	08/02/23	CI

Chart Cardiovascular Systems, Inc.

Duration

Period

More charts

Company Profile

Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company has developed orbital atherectomy systems (OAS) for both peripheral and coronary clinical applications. The primary base of its business is catheter-based platforms capable of treating a range of vessel sizes and plaque types, including calcified plaque. Its peripheral artery disease (PAD) products are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee, including calcified plaque. Its coronary artery disease (CAD) product, the Diamondback 360 Coronary OAS (Coronary OAS), is a catheter-based platform designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to de novo, severely calcified coronary artery lesions.

Sector

Medical Equipment, Supplies & Distribution

More about the company

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ABBOTT LABORATORIES	-5.81%	180B
MEDTRONIC PLC	-1.63%	106B
BECTON, DICKINSON AND COMPANY	-4.14%	67.55B
DEXCOM, INC.	-6.56%	46.11B
CENCORA, INC.	+13.22%	45.79B
HOYA CORPORATION	+2.58%	41.61B
METTLER-TOLEDO INTERNATIONAL, INC.	+19.93%	31.07B
TERUMO CORPORATION	+11.40%	24.77B
WEST PHARMACEUTICAL SERVICES, INC.	-5.36%	24.27B

Other Medical Equipment, Supplies & Distribution